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Mortality Risk Among Heart Failure Patients With Depression:
A Nationwide Population-Based Cohort Study
Kasper Adelborg, MD; Morten Schmidt, PhD; Jens Sundbøll, MD; Lars Pedersen, PhD; Poul Videbech, DMSc; Hans Erik Bøtker, DMSc;
Kenneth Egstrup, DMSc; Henrik Toft Sørensen, DMSc
Background-—The prevalence of depression is 4- to 5-fold higher in heart failure patients than in the general population.
We examined the inﬂuence of depression on all-cause mortality in patients with heart failure.
Methods and Results-—Using Danish medical registries, this nationwide population-based cohort study included all patients with a
ﬁrst-time hospitalization for heart failure (1995–2014). All-cause mortality risks and 19-year mortality rate ratios were estimated
based on Cox regression analysis, adjusting for age, sex, time period, comorbidity, and socioeconomic status. The analysis included
9636 patients with and 194 887 patients without a diagnosis of depression. Compared with patients without a history of
depression, those with depression had higher 1-year (36% versus 33%) and 5-year (68% versus 63%) mortality risks. Overall, the
adjusted mortality rate ratio was 1.03 (95% CI 1.01–1.06). Compared with no depression, the adjusted mortality rate ratios for
mild, moderate, and severe depression, as deﬁned by diagnostic codes, were 1.06 (95% CI 1.00–1.13), 1.03 (95% CI 0.99–1.08),
and 1.02 (95% CI 0.96–1.09), respectively. In a subcohort of patients, the mortality rate ratios were modiﬁed by left ventricular
ejection fraction, with adjusted mortality rate ratios of 1.17 (95% CI, 1.05–1.31) for ≤35%, 0.98 (95% CI 0.81–1.18) for 36% to 49%,
and 0.96 (95% CI 0.74–1.25) for ≥50%. Results were consistent after adjustment for alcohol abuse and smoking.
Conclusions-—A history of depression was an adverse prognostic factor for all-cause mortality in heart failure patients with left
ventricular ejection fraction ≤35% but not for other heart failure patients. ( J Am Heart Assoc. 2016;5:e004137 doi: 10.1161/
JAHA.116.004137)
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H eart failure is a major cause of hospitalization, morbid-ity, and mortality that affects >23 million people
worldwide.1 The prevalence of comorbid depression ranges
between 9% and 60% and is highest among heart failure
patients screened for depression, among women, and among
those with advanced heart failure.2
Depression and heart failure share underlying biological
mechanisms. Patients with depression have hyperactivity of
the hypothalamic–pituitary–adrenal axis, higher levels of
inﬂammatory markers, decreased heart rate variability, abnor-
malities in platelet function, lower compliance with medica-
tion and dietary guidelines, less social support, and a more
sedentary lifestyle than patients without depression. These
factors may aggravate cardiac dysfunction in heart failure
patients.3,4 Depressed heart failure patients appear to have a
1.5- to 2-fold higher risk of mortality than nondepressed heart
failure patients.2,5 Nevertheless, studies to date have been
limited by inclusion of highly selected patients6–11; short
follow-up periods (3 months to 3 years)6,7,12–14; use of self-
reported symptoms or antidepressant prescriptions as proxies
for depression6,7,9,10,12–15; limited control of confounding
factors such as smoking, alcohol use, socioeconomic factors,
and comorbidity9,10,13–15; and small sample size (<400
patients).6,7,9,10,15
Critical unanswered questions remain regarding the asso-
ciation between depression and mortality in subgroups of
heart failure patients deﬁned by sex, age group, left ventric-
ular ejection fraction (LVEF) values, causes of heart failure,
presence or absence of various comorbidities, and New York
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Heart Association (NYHA) functional classes. We hypothesized
that a history of depression is a prognostic factor for death in
heart failure patients and examined long-term mortality
among patients with and without a history of depression.
Methods
Setting and Design
This nationwide population-based cohort study, which used
prospectively collected data, was conducted from July 1,
1995, to February 1, 2014. Using the unique personal
identiﬁers assigned to all Danish residents at birth or at
immigration, we linked individual-level data from Danish
medical and administrative registries.16 The Danish national
health care system is government funded, ensuring equal and
free access to all medical care services provided by hospitals
and general practitioners.
Heart Failure Cohort
We identiﬁed all patients with a ﬁrst-time hospitalization for
heart failure (including primary and secondary diagnoses)
from the Danish National Patient Registry (DNPR).17 Admis-
sion date for the heart failure hospitalization deﬁned the index
date. The positive predictive value of heart failure diagnoses in
the DNPR is 81% with clinical examination as the reference
and 100% with information in medical records as the
reference.17
Depression
Information on all recorded diagnoses of depression any time
prior to the index date was obtained from the DNPR and the
Danish Psychiatric Central Research Register (DPCR).17,18 In
addition, we retrieved information on severity of depression
(mild, moderate, and severe) using codes from the Interna-
tional Classiﬁcation of Diseases, 10th Revision (ICD-10).
Patients with >1 depression diagnosis of any severity were
classiﬁed as being in the group with the most severe
depression. With an interview as the reference, the positive
predictive value of a single severe or moderate depression
episode in the DPCR is adequate (83% or 76%, respectively)
but is lower for mild depression (65%).19
Because many patients receive treatment for depression in
the primary care setting, depression may be underreported in
Danishmedical registries, which do not yet include primary care.
To compensate for suchunderreporting,weobtained information
on redeemed prescriptions for antidepressants. We divided
patients into 6 categories: (1) no diagnosis of depression and ≤1
redeemed prescription for antidepressants before the index date
(reference group); (2) no diagnosis of depression, >1 redeemed
prescription before the index date, and previous use of
antidepressants; (3) no diagnosis of depression, >1 redeemed
prescription for antidepressants before the index date, and
current useof antidepressants; (4) a depressiondiagnosis and≤1
redeemed prescription for antidepressants; (5) a depression
diagnosis, >1 redeemed prescription before the index date, and
previous use of antidepressants; and (6) a depression diagnosis,
>1 redeemed prescription before the index date, and current
antidepressant use. We deﬁned “current users” as having
redeemed a prescription for antidepressants within 90 days
before the index date. “Former users” redeemed their last
prescription >90 days before the index date. Data on redeemed
prescriptions of antidepressants were obtained from the Danish
Register of Medicinal Product Statistics, which has recorded all
dispensed prescriptions according to the Anatomical Therapeu-
tical Chemical (ATC) classiﬁcation system since 1995.20
Outcome
The study outcome was all-cause mortality. We used the
Danish Civil Registration System to ascertain mortality during
the years following the index date.16 This registry has
recorded dates of death and emigration, with daily updates
since 1968.16 We also examined immediate causes of deaths
using data from the Danish Register of Causes of Death21
(data available through December 31, 2012). We estimated
cardiovascular and noncardiovascular mortality in patients
with and without depression. For this analysis, depression
was deﬁned as any diagnosis or >1 prescription of antide-
pressant before the index date. Patients registered with only
an underlying and no immediate cause of death were
considered not to have an immediate cause of death;
however, the results did not change if the underlying cause
of death was considered as the immediate cause of death in
these patients (data not shown). Moreover, we speciﬁcally
examined deaths caused by arrhythmia, venous thromboem-
bolism, stroke, myocardial infarction, and heart failure.
Covariates
We collected information on a range of comorbidities
diagnosed from 1977 until the index date. These included
myocardial infarction, hypertension, atrial ﬁbrillation or atrial
ﬂutter, stroke, cancer, obesity, diabetes mellitus, chronic
pulmonary disease, chronic kidney disease, peptic ulcer,
illicit drug/alcohol/smoking abuse, dementia, anemia, and
peripheral artery disease. Data on these diagnoses were
obtained from the DNPR and the DPCR using ICD-8 codes
until 1994 and ICD-10 codes thereafter.17,18 We used all
available diagnoses other than emergency room diagnoses,
given the assumed low positive predictive value of the
latter.17
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Data on the following comedications used ≤90 and
>90 days before the index date were retrieved from the
Danish Register of Medicinal Product Statistics: antidepres-
sants, selective serotonin reuptake inhibitors, tricyclic antide-
pressants, anxiolytics or hypnotics, antipsychotics, statins,
low-dose aspirin, angiotensin-converting enzyme inhibitors or
angiotensin II receptor blockers, beta blockers, diuretics, and
nonsteroidal anti-inﬂammatory drugs.20 Data on socioeco-
nomic variables, including gross income, employment, and
education, were obtained from the Integrated Database for
Labor Market Research (for the index year or for previous
years, depending on data availability).22 For a subcohort of
heart failure patients, we retrieved data from the Danish Heart
Failure Registry on smoking status, alcohol habits, LVEF
values, and NYHA functional class.23 It has been mandatory
for cardiologists to register all incident hospitalized heart
failure cases in this nationwide registry since 2003. Patients
with ICD-10 codes for heart failure are enrolled in the registry
if they fulﬁll the European Society of Cardiology’s deﬁnition of
heart failure. Regular structured audits are conducted to
ensure the high quality of the registry’s data.23 All ICD and
ATC codes used in the study are provided in Table S1.
Statistical Analysis
All patients were followed from their admission date for heart
failure (index date) until the date of death or emigration or
September 1, 2014, whichever came ﬁrst. We compiled
descriptive data on the covariates described in the previous
section. The Kaplan–Meier method was used to compute
mortality risks at 1, 5, 10, and 15 years, and we generated
survival curves for patientswithandwithout previousdepression.
Crude and adjusted hazard ratios were computed using Cox
proportional hazards regression analysis comparing heart failure
patientswith andwithout a history of depression. Inmultivariable
analyses, we adjusted for age, sex, time periods, the comorbidi-
ties listed in Table 1, gross income, and employment.
In stratiﬁed analyses, we examined potential interactions
on a relative scale according to time periods, age groups, sex,
heart failure cause, LVEF, NYHA class, comorbidity, comed-
ication use, and socioeconomic factors. The analyses strat-
iﬁed by LVEF group and NYHA class were restricted to
patients with complete data on these variables. Because age
was nonlinear, it was included in the models as the best-ﬁtting
second-degree fractional polynomial. We evaluated propor-
tional hazards using log-log plots and found no violation of the
assumption.
Sensitivity Analyses
To test the robustness of our estimates, we performed several
sensitivity analyses. First, we analyzed patients whose ﬁrst
Table 1. Characteristics of Heart Failure Patients With and
Without Previous Depression
No Depression Previous Depression
Number 194 887 (95) 9636 (5)
Median age (25th to
75th percentiles), y
78 (68–84) 77 (67–84)
Women 89 671 (46) 6039 (63)
Time period
1995–1999 49 498 (25) 1801 (19)
2000–2004 59 842 (31) 2850 (30)
2005–2009 48 796 (25) 2792 (29)
2010–2014 36 751 (19) 2193 (23)
Comorbidity
Myocardial infarction 39 761 (20) 1770 (18)
Hypertension 50 303 (26) 3100 (32)
Atrial fibrillation/atrial flutter 38 175 (20) 1734 (18)
Stroke 21 968 (11) 1517 (16)
Cancer 31 198 (16) 1691 (18)
Obesity 10 728 (6) 827 (9)
Diabetes mellitus 26 724 (14) 1509 (16)
Chronic pulmonary disease 33 815 (17) 2369 (25)
Chronic kidney disease 9431 (5) 582 (6)
Peptic ulcer 17 751 (9) 1404 (15)
illicit drug/alcohol/
smoking abuse
9989 (5) 2358 (24)
Dementia 6483 (3) 1219 (13)
Anemia 17 345 (9) 1337 (14)
Peripheral artery disease 6077 (3) 369 (4)
Comedication in the prior 90 days
Antidepressants 24 239 (12) 5814 (60)
SSRIs 16 358 (8) 3316 (34)
TCAs 4133 (2) 1104 (12)
Anxiolytics or hypnotics 50 070 (26) 4793 (50)
Antipsychotics 8238 (4) 2239 (23)
Statins 30 164 (15) 1578 (16)
Low-dose aspirin 60 214 (31) 3191 (33)
ACEI/ARB 55 582 (29) 2466 (26)
Beta blockers 46 395 (24) 2121 (22)
Diuretics 100 130 (51) 5143 (53)
NSAIDs 30 000 (15) 1586 (16)
Income
Low 41 640 (21) 1654 (17)
Intermediate 52 031 (27) 2732 (28)
High 50 304 (26) 3082 (32)
Very high 50 912 (26) 2168 (23)
Continued
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diagnosis of depression was recorded in the DNPR separately
from those whose ﬁrst diagnosis was recorded in the DPCR.
Second, we restricted our analysis to depression diagnoses
occurring 1, 2, and 3 years before the index date. Third, we
ﬁtted 3 additional multivariable models, adjusted for educa-
tion (omitted from the main model because data on education
were missing for heart failure patients with a high age, and
thus these data were missing not at random), use of
anxiolytics or hypnotics, and use of antipsychotics. Fourth,
we omitted myocardial infarction, stroke, hypertension, and
diabetes mellitus because these covariates potentially could
represent intermediate variables in the association between
depression and all-cause mortality.24–26 Finally, to increase
the positive predictive value of the recorded diagnosis of heart
failure, we repeated the main analysis restricted to patients
included in the Danish Heart Failure Registry. In this
subcohort, we also adjusted for smoking and alcohol habits
as categorical variables in a complete-case analysis and used
multiple imputation with chained equations to create 25 data
sets with imputed values for smoking and alcohol.27 We
assumed that data were missing at random, and in the
imputation model, we included the covariates from the main
model and those presented in Table 1 (except for nons-
teroidal anti-inﬂammatory drugs, tricyclic antidepressants,
and education), the outcome indicator, and the Nelson-Aalen
cumulative baseline hazard. Finally, because depression can
be difﬁcult to assess in patients with illicit drug/alcohol/
smoking abuse, or dementia, we repeated the analysis
excluding these patients.
All analyses were performed using Stata version 14
(StataCorp LP). The study was approved by the Danish Data
Protection Agency (record 1-16-02-268-14). No approval from
an ethics committee or patient informed consent is required
for registry-based studies conducted in Denmark.
Results
Overall, 205 719 patients with a ﬁrst-time hospitalization for
heart failure were eligible for analysis. We excluded 99
patients with negative follow-up time, 9 patients with missing
data on age, and 1088 patients with missing data on gross
income and employment. After these exclusions, 9636 heart
failure patients with previous depression (5%) and 194 887
heart failure patients without depression (95%) were available
for analysis. Median follow-up time was 844 days (25th to
75th percentiles: 164–2050 days) for patients without
depression and 688 days (25th to 75th percentiles: 119–
1737 days) for patients with previous depression. Median age
was 78 years in patients without depression and 77 years in
patients with depression. A higher proportion of patients with
depression were women compared with patients without
depression. Apart from hypertension, the groups were
balanced in terms of cardiac comorbidities. Patients with a
history of depression had a higher prevalence of noncardiac
conditions than patients without depression (Table 1 and
Table S2). We identiﬁed 29 854 heart failure patients from the
Danish Heart Failure Registry. Descriptive data on these
patients are provided in Table S3.
Mortality
Mortality risks among heart failure patients with depression
were higher than among heart failure patients without
depression (Table 2 and Figure S1). Compared with patients
without depression, 19-year mortality rate ratios after multi-
variable adjustment were 1.03 (95% CI 1.01–1.06) overall,
1.06 (95% CI 1.00–1.13) for mild depression, 1.03 (95% CI
0.99–1.08) for moderate depression, and 1.02 (95% CI 0.96–
1.09) for severe depression (Table 3). Slightly more positive
associations were found with various combinations of
depression diagnoses and antidepressant use (Table 4 and
Table S2). Patients with previous depression had higher
noncardiovascular mortality and slightly higher cardiovascular
mortality than patients without previous depression (Table 5).
Age, Sex, Heart Failure Severity, Heart Failure
Cause, and Comorbidity
No interactions were found by age, sex, NYHA class, and
cause of heart failure (Figure and Figure S2). Among patients
Table 1. Continued
No Depression Previous Depression
Employment
Employed 25 618 (13) 557 (6)
Early retirement: receiving
sickness, disability, or
early retirement benefits
2649 (1) 145 (2)
Unemployed 20 163 (10) 1592 (17)
State pension 146 457 (75) 7342 (76)
Education
Basic education,
primary school
74 173 (38) 4288 (45)
Youth education,
high school, or similar
43 145 (22) 2045 (22)
Higher education 15 199 (8) 827 (9)
Unknown 62 370 (32) 2476 (26)
Data are shown as number (percentage), except as otherwise indicated. ACEI indicates
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAIDs,
nonsteroidal anti-inﬂammatory drugs; SSRIs, selective serotonin reuptake inhibitors;
TCAs, tricyclic antidepressants.
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with LVEF values ≤35%, those with a history of depression had
20% higher mortality than those who never had depression
(Figure). Stratiﬁed analyses among patients with various
comorbidities and comedications and according to gross
income, employment, and education showed no interactions
(Figures S3 through S5).
Sensitivity Analyses
Separate analyses of the prognostic impact of depression
based on cases registered in the DNPR and the DPCR agreed
with the main results (all sensitivity analyses are reported in
Table S4). When patients with depression diagnosed within 1,
2, and 3 years before the index date were excluded, the
results remained similar to the overall estimates. Repeating
the analyses restricted to heart failure patients included in the
Danish Heart Failure Registry also did not change the overall
estimates. The estimates remained unchanged among
patients included in this subcohort when we extended the
Cox model by adjusting for education, use of anxiolytics or
hypnotics, and use of antipsychotics, as well as for smoking
and alcohol use (in a complete case analysis and using
multiple imputation). Similarly, the main results were
unchanged when myocardial infarction, stroke, hypertension,
and diabetes mellitus were omitted from the multivariable
model and when we repeated the analysis excluding patients
with illicit drug/alcohol/smoking abuse, or dementia from the
cohort. Analyses stratiﬁed by time periods did not change the
results appreciably (Table S5).
Discussion
In this cohort study of patients with a ﬁrst-time hospitalization
for heart failure, depression was a prognostic factor for all-
cause mortality in patients with LVEF ≤35%; however, in other
heart failure patients, a history of depression was not
associated with all-cause mortality. The prognostic effect of
depression showed no interaction with age, sex, heart failure
causes, NYHA class, cardiac comorbidities, and noncardiac
comorbidities.
A meta-analysis of 8 studies demonstrated that comorbid
depression was an adverse prognostic factor for all-cause
mortality in heart failure patients (overall adjusted relative risk
2.10, 95% CI 1.71–2.58).2 Consistent with this result, another
meta-analysis of 9 studies including 4012 heart failure
patients reported adjusted relative risk of all-cause mortality
of 1.51 (95% CI 1.19–1.91) and adjusted relative risk of
cardiovascular mortality of 2.19 (95% CI 1.46–3.29).5 Severe
depression was associated with increased mortality (relative
risk 1.98, 95% CI 1.23–3.19) but not with mild depression
(overall adjusted relative risk 1.04, 95% CI 0.75–1.45).5
The disparity between our results and those of the meta-
analyses may have several explanations. Unlike our study,
studies in the meta-analyses used self-reported symptoms to
diagnose depression. Self-reported depression likely mimics
somatic symptoms and could reﬂect increasing heart failure
severity, which, if not sufﬁciently accounted for in the
analyses, could explain the poor prognosis of patients with
depression reported in previous studies.2,5 In addition, some
studies were not able to account for confounding factors such
as socioeconomic factors, smoking, and alcohol use, which
could have led to overestimation of the impact of depression
on mortality.9,10,13–15
In contrast to previous studies investigating the preva-
lence of comorbid depression, we retrieved data on at least
15 years of depression history. Even so, the prevalence of
depression was lower in our cohort (5%) than reported
previously.2 This may be attributed to our strict deﬁnition of
Table 2. Mortality Risks (Percentage) Among Heart Failure Patients With and Without Previous Depression
1 Year (95% CI) 5 Years (95% CI) 10 Years (95% CI) 15 Years (95% CI)
No depression 32.6 (32.4–32.9) 63.3 (63.0–63.5) 81.5 (81.3–81.8) 90.4 (90.2–90.6)
Depression 36.4 (35.4–37.3) 68.0 (67.0–69.0) 85.7 (84.8–86.5) 93.3 (92.3–94.1)
Table 3. The 19-Year MRRs in Heart Failure Patients With
and Without Depression, Overall and by Depression Severity
Crude MRR (95% CI)
Adjusted MRR
(95% CI)*
No depression Reference Reference
Depression overall†
(n=9636)
1.14 (1.12–1.17) 1.03 (1.01–1.06)
Mild depression‡
(n=1379)
1.27 (1.20–1.35) 1.06 (1.00–1.13)
Moderate depression‡
(n=2914)
1.16 (1.11–1.21) 1.03 (0.99–1.08)
Severe depression‡
(n=1305)
1.05 (0.99–1.12) 1.02 (0.96–1.09)
ICD indicates International Classiﬁcation of Diseases; MRR, mortality rate ratio.
*Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial ﬁbrillation
or atrial ﬂutter, stroke, cancer, obesity, diabetes mellitus, chronic kidney disease, peptic
ulcer, chronic pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anemia,
peripheral artery disease, gross income, and employment.
†Including all ICD codes for depression.
‡Speciﬁc ICD-10 codes are provided in Table S1.
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depression history, use of ICD codes, and restriction to
patients with incident heart failure. When we deﬁned
previous depression using both diagnosed depression and
use of antidepressants, the prevalence increased to 24%
(Table 4), which is in accordance with the existing
literature.2
Our results extend the results of previous studies.
Supporting our ﬁndings, the US Cardiovascular Health Study
demonstrated that patients with depression and elevated NT-
proBNP had substantially increased all-cause mortality (haz-
ard ratio 3.72, 95% CI 2.20–6.37) and cardiovascular
mortality (hazard ratio 5.42, 95% CI 2.38–12.36) compared
with patients without depression and with low NT-proBNP
levels.15 The prevalence of depression has been found to
increase with severity of heart failure symptoms, from 11%
among patients in NYHA class 1 to 20% in NYHA class 2, 38%
in NYHA class 3, and 42% in NYHA class 42; however, we did
not ﬁnd that depression was an adverse prognostic factor in
different NYHA classes. Nevertheless, standardized diagnostic
measures of depression could be particularly important for
patients with LVEF ≤35%.
Several pathophysiological and psychosocial mechanisms
in patients with depression and heart failure may underlie the
higher mortality observed for patients with LVEF ≤35%.3,4
Evidence suggests that patients with ongoing or remitted
depression have disturbances in the hypothalamic–pituitary–
adrenal axis, including higher cortisol levels than persons
without depression. This may augment the sympathetic
hyperactivity observed in advanced heart failure.28 Cortisol
has negative cardiovascular side effects, such as elevation of
blood pressure, truncal obesity, hyperinsulinemia, hyper-
glycemia, insulin resistance, dyslipidemia, and increased
plasma volume, which could worsen the prognosis of
advanced heart failure patients.29 Inﬂammatory cytokines
such as tumor necrosis factor, interleukin 1, and interleukin 6
also are elevated in patients with heart failure, and these
cytokines may be implicated in disease progression.3 Eleva-
tion of these cytokines is also characteristic of depression
Table 5. Cardiovascular and Noncardiovascular Mortality in Patients With and Without Previous Depression, 1995–2012
Rate Per 1000 Person-Years (95% CI)
Adjusted MRR (95% CI)*No Depression (n=149 235) Depression (n=45 224)
All-cause mortality 194.1 (193.0–195.2) 255.7 (253.1–258.3) 1.14 (1.12–1.15)
Cardiovascular mortality 70.3 (69.6–71.0) 86.0 (84.4–87.7) 1.09 (1.06–1.11)
Arrhythmia 7.6 (7.4–7.9) 8.9 (8.4–9.5) 1.08 (1.01–1.16)
Venous thromboembolism 1.7 (1.6–1.8) 2.3 (2.1–2.6) 1.15 (1.00–1.32)
Myocardial infarction 9.3 (9.0–9.6) 11.6 (11.0–12.3) 1.02 (0.97–1.09)
Stroke 6.5 (6.3–6.7) 9.2 (8.7–9.8) 1.12 (1.05–1.21)
Heart failure 23.4 (23.0–23.8) 29.8 (28.9–30.8) 1.08 (1.04–1.13)
Noncardiovascular mortality 108.9 (108.0–109.8) 160.2 (158.0–162.5) 1.19 (1.17–1.21)
MRR indicates mortality rate ratio.
*Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial ﬁbrillation or atrial ﬂutter, stroke, cancer, obesity, diabetes mellitus, chronic kidney disease, peptic ulcer,
chronic pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anemia, peripheral artery disease, gross income, and employment.
Table 4. The 19-Year MRRs in Heart Failure Patients According to Depression Diagnosis and Use of Antidepressants Before the
Index Date
Use of Antidepressants Crude MRR (95% CI) Adjusted MRR (95% CI)*
No depression No use (n=156 168) Reference Reference
Former use (n=16 457) 1.08 (1.06–1.10) 1.07 (1.05–1.09)
Current use (n=22 262) 1.37 (1.34–1.39) 1.21 (1.19–1.23)
Depression No use (n=1912) 1.07 (1.02–1.13) 1.00 (0.95–1.06)
Former use (n=2007) 1.07 (1.01–1.13) 1.00 (0.95–1.06)
Current use (n=5717) 1.28 (1.25–1.32) 1.10 (1.06–1.13)
MRR indicates mortality rate ratio.
*Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial ﬁbrillation or atrial ﬂutter, stroke, cancer, obesity, diabetes mellitus, chronic kidney disease, peptic ulcer,
chronic pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anemia, peripheral arterial disease, gross income, and employment.
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and may further adversely affect prognosis of heart failure
patients with depression.3 Studies to date, however, have
found no association between depression severity and
cytokine response, indicating that these cytokines may be
trait markers for depression rather than markers of current
depression.3 Patients with depression also have decreased
heart rate variability, which is a predictor of increased
mortality and a prognostic factor for arrhythmias.3 Finally,
platelet abnormalities, noncompliance, poor social support,
and suicide have been proposed as other mechanisms
responsible for the adverse prognostic effect of depression
in heart failure patients with low LVEF.3
Our study is the ﬁrst nationwide population-based study to
address the association between depression and all-cause
mortality among heart failure patients. Strengths distinguish-
ing this study from previous studies include the nationwide
coverage and a sample size exceeding the combined number
of patients included in the previous 2 meta-analyses.2,5 This
enabled us to study the prognostic impact of depression in
several subgroups. We had no loss to follow-up, largely
avoiding selection bias. Our study also has limitations.
Because the validity of depression in the DNPR is unknown,
misclassiﬁcation of depression cannot be ruled out. We
sought to address this potential limitation by showing that
results were consistent when analyzed separately for cases
identiﬁed in the DNPR and in the DPCR and by reclassifying
depression using both diagnoses and antidepressant use;
however, we had only a few years of prescription history for
patients identiﬁed early in the study period. In addition,
antidepressants are used for indications other than depres-
sion, a fact that we were unable to take into account.
Consequently, some of the patients using an antidepressant
without being diagnosed with depression may be misclassiﬁed
as surrogates for a history of depression. Moreover, we had
Figure. The aMRRs with 95% CIs in subgroups of heart failure patients with and without depression. The
aMRRs were adjusted for age, sex, time period, myocardial infarction, hypertension, atrial ﬁbrillation or
atrial ﬂutter, stroke, cancer, obesity, diabetes mellitus, chronic kidney disease, peptic ulcer, chronic
pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anemia, peripheral artery disease, gross
income, and employment (except for the stratifying variable). aMRR indicates adjusted mortality rate ratio;
NYHA, New York Heart Association.
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data on depression severity for only about half of the patients,
and positive predictive values for codes for mild, moderate,
and severe depression were only moderate (65–83%). Another
concern is that the observational nature of the study design
did not permit us to exclude the risk of unmeasured
confounding. Nevertheless, we were able to adjust for known
prognostic comorbid conditions (anemia, chronic kidney
disease, peripheral artery disease, atrial ﬁbrillation, and
diabetes mellitus).30,31 Furthermore, we were able to adjust
for smoking, alcohol use, and socioeconomic status.
Conclusions
We found that depression was an adverse prognostic factor
for death in patients with LVEF ≤35%, but not in other heart
failure patients. Consequently, clinical attention to depression
seems particularly warranted for patients with advanced heart
failure.
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Table S1. International Classification of Diseases codes and Anatomical Therapeutic 
Classification codes used in the study.  
 ICD-8 ICD-10 ATC codes 
Heart failure  
 
42709, 42710, 42711, 
42719, 42899, 78249 
I110, I130, I132, I420, I426, 
I427, I428, I429, I500, I501, 
I502, I503, I508, I509 
N/A 
Depression  
 
29609, 29629, 29809, 
30049 
F32-F33 N/A 
Mild depression N/A F320, F3200, F3201, F330, 
F3300, F3301 
N/A 
Moderate depression  N/A F321, F3210, F3211, F331, 
F3310, F3311 
N/A 
Severe depression N/A F322, F323, F3230, F3231, 
F332, F333, F3330, F3331 
N/A 
Cardiac comorbidity    
Myocardial infarction 410 I21 N/A 
Heart valve disease 394-397 I05-I08, I098, I34-I37 N/A 
Myocarditis 422, 39129 
 
I40-I41, I090, I514 
 
N/A 
Hypertension 400-404 I10-I15 
 
N/A 
Angina pectoris 411, 413 I20, I251, I259 N/A 
Atrial fibrillation/atrial 
flutter 
42793, 42794 I48 N/A 
Cardiomyopathy 425 I42-I43 
 
N/A 
Non-cardiac 
comorbidities  
 
   
Stroke  430-434 I60-I61, I63-I64 N/A 
Cancer  140-209 C00-C96 N/A 
Obesity 277 E65-E66 N/A 
Diabetes  24900-24909 (excluding 
24902), 25000-25009 
(excluding 25002) 
E10 (excluding E102), E11 
(excluding E112), E14 
(excluding E142)  
N/A 
Chronic pulmonary 
disease 
490-493, 515-518 
 
J40-J47, J60-J67, J684, J701, 
J703, J841, J920, J961, J982-
J983 
N/A 
Chronic kidney disease  24902, 25002, 75310-
75319, 582-584, 59009, 
59320, 792 
E102, E112, E142, N03, N05, 
N110, N14, N16, N18-N19, 
N269, Q611-Q614 
N/A 
Peptic ulcer  53091, 53098, 531-534 K221, K25-K28 N/A 
Illicit 
drug/alcohol/smoking 
abuse* 
303-304 F10-F19 N/A 
Dementia*  29009-29019, 29309 F00-F03, G30 N/A 
Anaemia 280-281, 283-285 D50-55, D59, D61-D64   N/A 
Peripheral arterial disease 44389-44399 I739 N/A 
 
Comedication 
prescription <90 days 
   
Antidepressants N/A N/A N06A 
SSRIs N/A N/A N06AB 
TCAs N/A N/A N06AA 
Anxiolytics/hypnotics N/A N/A N05B, N05C 
Antipsychotics 
 
N/A N/A N05A 
Statins N/A N/A C10AA, C10B 
Low-dose aspirin N/A N/A B01AC06, 
N02BA01 
ACEI/ARBs N/A N/A C09A, C09B, 
C09C, C09D 
Betablockers N/A N/A C07 
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Diuretics N/A N/A C03 
NSAIDs N/A N/A M01A 
Causes of death     
Cardiovascular mortality N/A I00-I99 N/A 
Venous thromboembolism N/A I26, I80 N/A 
Myocardial infarction N/A I21-I23 N/A 
Stroke N/A I61, I63-I64 N/A 
Heart failure  N/A I50, I110, I130, I132 
 
N/A 
Arrhytmia N/A I44-I49 
 
N/A 
Non-cardiovascular 
mortality 
N/A All other codes than I00-I99 N/A 
Abbreviations: SSRIs, Selective serotonin inhibitors; TCAs: Tricyclic antidepressants; ACEI/ARBs: Angiotensin-converting enzyme 
inhibitors/Angiotensin II receptor blockers; NSAIDs, Nonsteroidal anti-inflammatory drugs  
*Data from the Danish National Patient Registry and the Danish Psychiatric Central Research Register. 
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Table S2. Descriptive data for patients with and without depression combining diagnoses and use of 
antidepressants.  
 No depression Depression 
 
 No use of 
antidepressants 
Former use of 
antidepressants 
Current use of 
antidepressants 
No use of 
antidepressants 
Former use of 
antidepressants 
Current use of 
antidepressants 
Median age (25th-75th 
percentiles) 
77 (68-84) 77 (67-84) 79 (70-85) 75 (66-81) 74 (64-83) 78 (69-85) 
Women  67,806 (43) 8954 (54) 12,911 (58) 1057 (55) 1166 (58) 3816 (67) 
Time period       
1995-1999 43,912 (28) 1,820 (11) 3,766 (17) 649 (34) 239 (12) 913 (16) 
2000-2004 48,178 (31) 4,606 (28) 7,058 (32) 603 (32) 551 (27) 1,696 (30) 
2005-2009 37,111 (24) 5,181 (31) 6,504 (29) 427 (22) 626 (31) 1,739 (30) 
2010-2014 26,967 (17) 4,850 (30) 4,934 (22) 233 (12) 591 (30) 1,369 (24) 
Comorbidity       
Myocardial infarction  31,945 (21) 3524 (21) 4292 (19) 387 (20) 411 (21) 972 (17) 
Hypertension 37,061 (24) 5869 (36) 7373 (33) 474 (25) 679 (34) 1947 (34) 
Atrial fibrillation/atrial 
flutter 
29,868 (19) 3623 (22) 4684 (21) 283 (15) 396 (20) 1055 (19) 
Stroke  14,787 (9) 2681 (16) 4500 (20) 238 (12) 322 (16) 957 (16) 
Cancer  24,083 (16) 3015 (18) 4100 (18) 275 (14) 366 (18) 1050 (18) 
Obesity 7675 (5) 1383 (9) 1670 (8) 157 (8) 213 (11) 467 (8) 
Diabetes  20,052 (13) 2883 (18) 3789 (17) 278 (15) 361 (18) 870 (15) 
Chronic pulmonary 
disease 
24,696 (16) 3845 (23) 5274 (24) 429 (22) 500 (25) 1440 (25) 
Chronic kidney disease  7018 (4) 1094 (7) 1319 (6) 116 (6) 140 (7) 326 (6) 
Peptic ulcer 12,868 (8) 1980 (12) 2903 (13) 271 (14) 306 (15) 827 (14) 
Illicit drug/alcohol abuse 6147 (4) 1723 (11) 2119 (10) 509 (27) 570 (28) 1279 (22) 
Dementia  3383 (2) 888 (5) 2212 (10) 136 (7) 244 (12) 839 (15) 
Anaemia  12,437 (8) 1982 (12) 2926 (13) 190 (10) 287 (14) 860 (15) 
Peripheral arterial 
disease 
4267 (3) 862 (5) 948 (4) 59 (3) 94 (5) 216 (4) 
Comedication < 90 
days 
      
Antidepressants 1977 (1) 0 (0) 22,262 (100) 97 (5) 0 (0) 5717 (100) 
SSRIs 1325 (0.9) 0 (0) 15,033 (68) 72 (4) 0 (0) 3244 (57) 
TCAs 253 (0.2) 0 (0) 3880 (17) 6 (0.3) 0 (0) 1098 (19) 
Anxiolytics/hypnotics 33,771 (22) 6281 (38) 10,018 (45) 705 (37) 887 (44) 3201 (56) 
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Antipsychotics 4599 (3) 1072 (7) 2567 (12) 338 (18) 347 (17) 1554 (27) 
Statins 22,634 (14) 3362 (20) 4168 (19) 217 (11) 347 (17) 1014 (18) 
Low-dose aspirin 46,153 (30) 5602 (34) 8459 (38) 536 (28) 620 (31) 2035 (36) 
ACEI/ARBs 43,925 (28) 5167 (31) 6490 (29) 443 (23) 531 (26) 1492 (26) 
Betablockers 36,578 (23) 4403 (27) 5414 (24) 361 (19) 477 (24) 1283 (23) 
Diuretics 78,477 (50) 8401 (51) 13,252 (60) 914 (48) 888 (44) 3341 (58) 
NSAIDs 23,122 (15) 2744 (17) 4134 (19) 296 (15) 308 (15) 982 (17) 
Income        
Low 35,301 (23) 2345 (14) 3994 (18) 493 (26) 270 (13) 891 (16) 
Intermediate 41,426 (27) 4209 (26) 6396 (29) 614 (32) 530 (26) 1588 (28) 
High 38,271 (25) 5266 (32) 6767 (30) 497 (26) 689 (34) 1896 (33) 
Very high 41,170 (26) 4637 (28) 5105 (23) 308 (16) 518 (26) 1342 (24) 
Employment       
Employed 22,497 (14) 1601 (10) 1520 (7) 134 (7) 142 (7) 281 (5) 
Early retirement, 
receiving 
sickness/incapacity/early 
retirement 
2197 (1) 238 (1) 214 (1) 24 (1) 40 (2) 81 (1) 
Unemployed 15,154 (10) 2426 (15) 2583 (12) 336 (18) 447 (22) 809 (14) 
State pensioner 116,320 (75) 12,192 (74) 17,945 (81) 1418 (74) 1378 (69) 4546 (80) 
Education       
Basic education, 
primary school 
57,997 (37) 6916 (42) 9260 (42) 899 (47) 878 (44) 2511 (44) 
Youth education, high 
school or similar 
34,551 (22) 4042 (25) 4552 (21) 396 (21) 511 (25) 1138 (20) 
Higher education 11,989 (8) 1548 (9) 1662 (7) 113 (6) 210 (11) 504 (9) 
Missing 51,631 (33) 3951 (24) 6788 (30) 504 (26) 408 (20) 1564 (27) 
Data are numbers (%).  
Abbreviations: SSRIs, Selective serotonin inhibitors; TCAs, Tricyclic antidepressants; ACEI/ARBs: Angiotensin-converting enzyme inhibitors/Angiotensin II receptor 
blockers; NSAIDs, Nonsteroidal anti-inflammatory drugs 
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Table S3. Characteristics of heart failure patients with and without depression 
registered in the Danish Heart Failure Registry (1 January 2003–1 February 
2014).  
 No depression Depression 
Number of patients 28,602 (96) 1252 (4) 
Left Ventricular Ejection Fraction   
>49% 1842 (6) 93 (7) 
36%-49% 5509 (19) 270 (22) 
<36% 17,948 (63) 714 (57) 
Missing 3303 (12) 175 (14) 
New York Heart Association 
(NYHA) classification 
  
NYHA Class I 2359 (8) 63 (5) 
NYHA Class II 10,838 (38) 425 (34) 
NYHA Class III 5798 (20) 299 (24) 
NYHA Class IV 649 (2) 28 (2) 
Missing 8958 (31) 437 (35) 
Alcohol intake   
Maximum 14 drinks for women and 21 
for men per week 
20,491 (72) 827 (66) 
More than 14 drinks for women and 21 
for men per week 
2075 (7) 125 (10) 
Missing  6036 (21) 300 (24) 
Smoking habits   
Smoker 7987 (28) 448 (36) 
Former smoker 9741 (34) 376 (30) 
Never smoker 6448 (23) 230 (18) 
Missing 4426 (15) 198 (16) 
Data are numbers (%).      
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Table S4. Sensitivity analyses: Mortality rate ratios comparing heart failure 
patients with and without depression. The number of patients with depression is 
reported in parentheses.    
 Crude mortality rate ratio 
(95% confidence intervals) 
Adjusted mortality rate ratio
*
 
(95% confidence intervals) 
Registry with first diagnosis of 
depression 
  
National Patient Registry (n=2325) 1.28 (1.23-1.34) 1.01 (0.97-1.06) 
Psychiatric Central Research 
Register 
(n=7311) 
1.10 (1.07-1.13) 1.04 (1.01-1.06) 
Years since first depression 
diagnosis  
  
Within 1 year (n=1253) 1.26 (1.19-1.34) 1.05 (0.99-1.12) 
Within 2 years (n=1991) 1.23 (1.17-1.29) 1.05 (1.00-1.10) 
Within 3 years (n=2578) 1.23 (1.18-1.29) 1.05 (1.00-1.10) 
Danish Heart Failure Registry 
cohort 
  
Depression vs. no depression  
(n=1252) 
1.24 (1.15-1.35) 1.07 (0.99-1.16) 
+ adjustment for smoking† (n=1054) 1.24 (1.14-1.35) 1.07 (0.97-1.17)‡ 
+ adjustment for alcohol† (n=952) 1.20 (1.09-1.31) 1.06 (0.96-1.16)‡ 
Additional adjustments
*
    
+ education† (n=7160) 1.25 (1.22-1.29) 1.04 (1.01-1.07) 
+ anxiolytics/hypnotics (n=9636) 1.14 (1.12-1.17) 1.00 (0.98-1.03) 
+ antipsychotics (n=9636) 1.14 (1.12-1.17) 0.99 (0.96-1.01) 
No adjustment for myocardial 
infarction, stroke, hypertension, and 
diabetes (n=9636) 
1.14 (1.12-1.17) 1.04 (1.01-1.06) 
Excluding patients with illicit 
drug/alcohol/smoking abuse or 
dementia 
  
Depression vs. no depression  
(n=6,331) 
1.12 (1.09-1.16) 1.08 (1.05-1.11) 
*Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial fibrillation/atrial flutter, stroke, cancer, obesity, 
diabetes, chronic kidney disease, peptic ulcer, chronic pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anaemia, 
peripheral arterial disease, gross income, and employment.   
†Analyses restricted to patients with complete data on all variables.   
‡Using multiple imputation, the adjusted mortality rate ratio, including adjustment for smoking, was 1.09 (95% confidence 
interval: 1.00-1.18) and the adjusted mortality rate ratio, including adjustment for alcohol, was 1.09 (95% confidence interval: 
1.01-1.18) 
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Table S5. Mortality rate ratios in heart failure patients according to depression diagnosis 
and use of antidepressants before the index date, by time periods.  
Diagnosis Use of antidepressants Crude mortality rate 
ratio 
(95% confidence 
intervals) 
Adjusted mortality ratio 
(95% confidence 
intervals)
*
 
1995-1999    
No depression - Reference Reference 
Depression - 1.13 (1.08-1.19) 1.07 (1.02-1.13) 
No depression 
No use Reference Reference 
Former use 1.17 (1.11-1.22) 1.09 (1.04-1.14) 
Current use 1.28 (1.24-1.33) 1.20 (1.16-1.24) 
Depression 
No use 1.14 (1.05-1.23) 1.07 (0.99-1.16) 
Former use 1.33 (1.17-1.52) 1.27 (1.11-1.44) 
Current use 1.14 (1.06-1.22) 1.06 (0-99-1.14) 
2000-2004    
No depression - Reference Reference 
Depression - 1.12 (1.08-1.17) 0.99 (0.95-1.03) 
No depression 
No use Reference Reference 
Former use 1.18 (1.14-1.22) 1.09 (1.06-1.13) 
Current use 1.37 (1.34-1.41) 1.18 (1.15-1.22) 
Depression 
No use 1.00 (0.91-1.09) 0.96 (0.88-1.05) 
Former use 1.13 (1.03-1.24) 0.94 (0.86-1.03) 
Current use 1.27 (1.21-1.34) 1.06 (1.01-1.12) 
2005-2009    
No depression - Reference Reference 
Depression - 1.19 (1.14-1.25) 1.02 (0.97-1.07) 
No depression 
No use Reference Reference 
Former use 1.14 (1.10-1.18) 1.05 (1.02-1.09) 
Current use 1.50 (1.45-1.54) 1.22 (1.18-1.26) 
Depression 
No use 1.02 (0.90-1.14) 0.92 (0.82-1.04) 
Former use 1.09 (0.99-1.20) 0.93 (0.85-1.03) 
Current use 1.43 (1.36-1.51) 1.11 (1.05-1.18) 
2010-2014    
No depression - Reference Reference 
Depression - 1.26 (1.19-1.34) 1.07 (1.00-1.14) 
No depression No use Reference Reference 
 Former use 1.07 (1.02-1.12) 1.02 (0.97-1.07) 
 Current use 1.52 (1.46-1.59) 1.22 (1.17-1.28) 
Depression No use 1.12 (0.92-1.36) 1.03 (0.85-1.26) 
 Former use 1.06 (0.93-1.20) 1.02 (0.89-1.16) 
 Current use 1.54 (1.43-1.66) 1.14 (1.06-1.24) 
*
Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial fibrillation/atrial flutter, 
stroke, cancer, obesity, diabetes, chronic kidney disease, peptic ulcer, chronic pulmonary disease, illicit 
drug/alcohol/smoking abuse, dementia, anaemia, peripheral arterial disease, gross income, and 
employment.  
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Figure S1. Kaplan-Meier survival curve for heart failure patients with and without 
depression.  
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Figure S2. Adjusted mortality rate ratios with 95% confidence intervals by age and sex 
comparing heart failure patients with and without depression.  
 
Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial fibrillation/atrial flutter, stroke, cancer, obesity, diabetes, chronic 
kidney disease, peptic ulcer, chronic pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anaemia, peripheral arterial disease, gross 
income, and employment.   
Abbreviations: aMRR, adjusted mortality rate ratio; CI, confidence interval 
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Figure S3. Comorbidity-stratified adjusted mortality rate ratios comparing heart failure 
patients with and without depression.  
 
Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial fibrillation/atrial flutter, stroke, cancer, obesity, diabetes, chronic 
kidney disease, peptic ulcer, chronic pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anaemia, peripheral arterial disease, gross 
income, and employment (except for the stratifying variable). 
Abbreviations: aMRR, adjusted mortality rate ratio; CI, confidence interval 
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Figure S4. Adjusted mortality rate ratios comparing heart failure patients with and 
without depression according to use of comedications within 90 days prior to the index 
date.  
 
Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial fibrillation/atrial flutter, stroke, cancer, obesity, diabetes, chronic 
kidney disease, peptic ulcer, chronic pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anaemia, peripheral arterial disease, gross 
income, and employment.  
Abbreviations: aMRR, adjusted mortality rate ratio; CI, confidence interval; SSRIs, Selective serotonin inhibitors; TCAs, Tricyclic 
antidepressants; ACEI/ARB, Angiotensin-converting enzyme inhibitors/Angiotensin II receptor blockers; NSAIDs, Nonsteroidal anti-
inflammatory drugs 
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Figure S5. Adjusted mortality rate ratios comparing heart failure patients with and 
without depression according to socioeconomic status.  
 
Adjusted for age, sex, time period, myocardial infarction, hypertension, atrial fibrillation/atrial flutter, stroke, cancer, obesity, diabetes, chronic 
kidney disease, peptic ulcer, chronic pulmonary disease, illicit drug/alcohol/smoking abuse, dementia, anaemia, peripheral arterial disease, gross 
income, and employment (except for the stratifying variable). 
Abbreviations: aMRR, adjusted mortality rate ratio; CI, confidence interval 
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